After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...